<DrugInformationSummary id="CDR0000804623"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about idecabtagene vicleucel
         and a collection of links to more information about the use of 
         this drug, research results, and ongoing clinical trials.
  </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/Idecabtagenevicleucel">Idecabtagene Vicleucel</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000763837">idecabtagene vicleucel</TerminologyLink><GlossaryLink ref="CDR0000804621">idecabtagene vicleucel</GlossaryLink><USBrandNames><USBrandName>Abecma</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>I-deh-KAB-tuh-jeen vik-LOO-sel</TermPronunciation><MediaLink ref="CDR0000805403" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000805964" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b90c1fe7-f5cc-464e-958a-af36e9c26d7c&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Idecabtagene Vicleucel</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b90c1fe7-f5cc-464e-958a-af36e9c26d7c&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Idecabtagene vicleucel
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045793" dictionary="Cancer.gov" audience="Patient">multiple myeloma</GlossaryTermRef></Strong> that has come back or did not respond to treatment. It is used in adults who have received at least two lines of treatment that included an <GlossaryTermRef href="CDR0000739791" dictionary="Cancer.gov" audience="Patient">immunomodulating agent</GlossaryTermRef>, a <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitor</GlossaryTermRef>, and an <GlossaryTermRef href="CDR0000798792" dictionary="Cancer.gov" audience="Patient">anti-CD38 monoclonal antibody</GlossaryTermRef></ListItem>
   </ItemizedList>
  <Para id="_5">It is used in adults who have received at least two lines of treatment that included an <GlossaryTermRef href="CDR0000739791" dictionary="Cancer.gov" audience="Patient">immunomodulating agent</GlossaryTermRef>, a <GlossaryTermRef href="CDR0000393541" dictionary="Cancer.gov" audience="Patient">proteasome inhibitor</GlossaryTermRef>, and an <GlossaryTermRef href="CDR0000798792" dictionary="Cancer.gov" audience="Patient">anti-CD38 monoclonal antibody</GlossaryTermRef>.</Para><Para id="_4">Idecabtagene vicleucel is only available as part of a program called Abecma REMS (<ExternalRef xref="https://www.abecmarems.com/">Risk Evaluation and Mitigation Strategies</ExternalRef>).</Para>
 </Section><Section id="_About"><Title>More About Idecabtagene Vicleucel</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/763837">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.49">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a621024.html">Idecabtagene Vicleucel</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.50"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.51">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers">Understanding the Risk of Second Cancers After CAR T-Cell Therapy</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy">T-cell Transfer Therapy</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/research/car-t-cells">CAR T Cells: Engineering Patientsâ€™ Immune Cells to Treat Their Cancers</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C117729">Find Clinical Trials for Idecabtagene Vicleucel</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2021-04-16</DateFirstPublished><DateLastModified>2025-04-24</DateLastModified></DrugInformationSummary>
